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 1. 0 Introduction 
 The purpose of this project is to establish an early detection marker for 
patients with sepsis or septic shock. The current protocol to diagnose sepsis results 
in late detection. Lactate is currently used as a primary marker and once levels are 
higher than 4millimol/L, the patient is said to have sepsis. There are not defined 
levels for the stages of sepsis. In many cases the patient symptoms worsen quickly 
and invasive procedures need to be utilized for treatment. Further research into 
early goal directed therapy as a solution for early detection has the potential to give 
the patients better treatment prior to the development of severe sepsis or septic 
shock.  
1.1 MQP Objectives 
 The hypothesis of the project is that platelet closure time will aid in early 
detection of sepsis. The first goal to validate the correlation between platelet closure 
time (PCT) and sepsis will be to analyze the PCT in 50 patients that fit the study 
criteria.  The subsequent goal is to establish a correlation between lactate as 
biomarker and PCT. 
2.0 Literature Background 
2.1 Statistics 
Sepsis is currently the leading cause of death in intensive care units as well as 
the eleventh cause of death in the United States. However, sepsis does not receive 
the research funding or publicity that other diseases such as acquired immune 
deficiency syndrome (AIDS), cardiac failure, and various cancers receive (Offord 
2002). Approximately 750,000 cases of sepsis are diagnosed each year. The average 
cost of treating one sepsis case is $22,100, which totals 16.7 billion dollars annually 
in the United States (Offord 2002). The high mortality rate of sepsis results in 
approximately 215,000 deaths of the 750,000 cases. This is an extremely high rate 
for a disease that has such little public awareness and research funding (Offord, 
2002). Due to the lack of funding there is still no definitive early biomarker that 
indicates a patient is about to become septic or go into septic shock. Currently, 
Emergency Room physicians rely on lactate levels as a definitive marker. When a 
lactate level is 4 millimol/L, it is clear that invasive goal-directed therapy is needed. 
However, when a lactate level is higher than normal, such as a 2 millimol/L it is 
unclear how to treat the patient. If there was an additional indicator that confirmed 
the patients’ status, treatment could be started early with a potentially more 
successful outcome.  
 
2.2 Sepsis 
Sepsis is a systemic disease caused by a bacterial infection. The systemic 
infection leads to a body’s natural response in release of inflammatory mediators. 
An increase in cardiac output is the body’s first heightened immune response. A 
patient is diagnosed with sepsis when their initial symptoms are fever, tachypnoea 
(rapid, shallow breathing), and tachycardia (increased heart rate) (Offord,2002). 
There are a variety of microbial pathogens that can lead to the symptoms that 
classify a patient as septic. 
2.2.1 Symptoms and Signs 
 
There are several stages of sepsis that range from systemic inflammatory 
response syndrome (SIRS) to septic shock. The progression of each stage is 
displayed below in Table 1. 
 
Table 1: ACCP/SCCM Consensus Definition for Sepsis and Organ Failure (Offord, 2002). 
 
 
The infections are commonly caused by gram-negative bacteria, which can 
originate in the lungs, abdomen, or urinary tract. Most cases seen are pulmonary 
infections. Upon entry into the Emergency Room if the patient appears to have two 
or more systemic inflammatory response syndrome (SIRS) symptoms (as listed in 
Table 1) along with a confirmed infection the patient is diagnosed as septic.  In 
order for sepsis to progress to severe sepsis there must be signs of acute organ 
dysfunction. Severe sepsis accompanied by cardiovascular dysfunction and low 
blood pressure, is categorized as septic shock. An early detection marker could be 
crucial allowing physicians to start treatment before the patient enters the intensive 
care unit (ICU), as this disease can progress at a rapid pace (Offord, 2002). 
In order to make early detection feasible it is important to study the factors 
that lead to organ failure in sepsis patients. This study is focusing on identifying the 
connection between the systemic inflammatory cascade and the coagulation 
cascade. If a better understanding is obtained, there may possibly be an early 
coagulation biomarker that could be used rather than relying on a systemic 
inflammatory marker such as lactate levels as in the current practice. 
2.2.2 Early Goal Directed Therapy in Sepsis Patients 
 
 There has been an increase in successful outcomes of conditions such as 
stroke and acute myocardial infarctions due to early diagnosis and time-sensitive 
therapy at the proximal stage. This same practice applied to sepsis could potentially 
lead to improvements in the outcome of the patients. Early goal directed therapy 
(EGDT) is a complex strategy (Otero, pp. ,2006). Often therapy initiatives are started 
once the patient is transferred to the ICU. However, if early-goal directed therapy 
can help prevent sudden cardiovascular collapse then the need for vasopressors, 
mechanical ventilation, and pulmonary-artery catheterization decreases. Global 
tissue hypoxia is determined by a high lactate concentration. Hypoxia also 
stimulates systemic inflammatory response syndrome (SIRS). Early goal directed 
therapy does have its risks. It involves putting a central venous catheter into the 
patient so that the central venous oxygen saturation, the amount of oxygen 
saturation in the vena cava of the heart (ScV02), can be monitored and adjusted to 
help lower tissue hypoxia. Inserting a central venous catheter has many risk factors 
and is a big step to take. Early goal-directed therapy is a new concept being applied 
in order to prevent the negative outcomes of sepsis.  Due to the delay in detecting 
sepsis with lactate, this study is focusing on a coagulation biomarker to help decide 
if the patient’s symptoms are severe enough for early goal directed therapy 
2.3 Lactate as a Gold Standard 
 Clinical evaluation and laboratory testing are the primary sources of 
information for any patient with the potential of being diagnosed with severe sepsis 
or septic shock. These findings are specific to signs of infection, organ dysfunction 
and global tissue hypoxia. The laboratory data obtained are used as biomarkers. Any 
laboratory abnormalities that are within the criteria for sepsis can be used in aiding 
the correct diagnoses and treatments. An example of an initial test that is run is a 
complete blood cells count (CBC) that includes a standard chemistry panel of 
bicarbonate, liver enzymes, lactate, creatinine, white blood cells (WBC) and 
coagulation studies. CBCs are an extremely vital indicator of the present of bacteria 
and severity of infection. If the WBC count is high it usually indicates the presence of 
an infection. If lactate levels are high it indicates global tissue hypoxia. Creatinine 
levels indicate kidney function. The CBC is usually run regardless of the initial 
symptoms in order to see what is going on with the biochemistry within the body, 
and can at times explain the symptoms being seen. The downside to using a CBC as 
an indicator of a bacterial infection is its lack of specificity. Therefore the CBC alone 
cannot be used to make a final diagnosis.   
Among the estimated 80 different biological markers for sepsis, lactate levels 
are currently the main test for global tissue hypoxia. In a majority of instances, 
elevated lactate levels in the emergency department due to an infection leads to a 
poor prognosis for the patient (Talan, 2008)  
2.3.1 Lactate- How it Works Within The Body 
 
 The normal plasma lactate concentration is approximately 0.3-1.3 
millimol/L. During normal lactate production glycolysis in the cytoplasm produces 
pyruvate, which is then converted into acetyl CoA during aerobic conditions. The 
acetyl CoA then enters the Krebs cycle which produces 36 ATP via the electron 
transport chain. Lactate is produced when anaerobic conditions are present. The 
pyruvate is converted into lactic acid by the enzyme lactate dehydrogenase. The 
lactic acid is then dissociated into lactate addition of 2 hydrogens, resulting in the 
regeneration of NAD from NADH. However, acidosis can occur if the oxidative 
pathway is impaired and a surplus of H+ is present. NADH also controls the 
conversion of pyruvate to lactate. Tissues that require a lot of ATP need the cells to 
go through aerobic metabolism, therefore the NADH levels need to be kept low. The 
liver removes approximately 70% of the lactate by metabolizing it and releasing it 
into the bloodstream (Bolton, 2007). This is the lactate produced during anaerobic 
metabolism (Phypers, 2006). This process is demonstrated in Figure 1 below.  
 Figure 1: Glycolysis, Kreb's Cycle, and Oxidative Phosphorylation (Phypers) 
2.2.2 Lactate and Sepsis 
 
 High levels of the lactate produced during anaerobic metabolism are used as 
the main indicator for tissue hypoxia. The anaerobic pathway involves metabolism 
of lactate back into pyruvate by well-oxygenated organs like the liver, heart kidneys 
and brain. In cases of sepsis or septic shock, when the organs become hypoxic, the 
production of lactate exceeds the rate at which an organ, such as the liver can 
metabolize it. Therefore the lactate builds up in the bloodstream, and basis of lactate 
measurement is from the blood (Bolton).  
 Another reason for high lactate levels in patients with sepsis could be due to 
Type A lactic acidosis. Type A lactic acidosis is when there is decreased oxygen 
delivery or increased oxygen demand. This belief has been challenged over the past 
decade. If this were true and hypoxia  were the primary reason for the increase in 
levels, stimulation with pyruvate dehydrogenase (PDH) by dichloroacetate should 
have been able to decrease the levels of pyruvate and lactate.  
2.3 Coagulation 
2.3.1 Coagulation and Inflammatory Cascades  
 
The current treatments for sepsis using antibiotics and vasopressors are 
limited in decreasing the mortality rate. In order to establish a more appropriate 
course of treatment, it is important to study the pathophysiology and cellular 
mechanisms involved in the inflammatory response related to sepsis.  
Endotoxin is a molecule derived from gram-negative bacteria’s membrane. It 
is the initial stimulus that causes the cellular release of cytokines.  It has the ability 
to activate macrophages and endothelial cells, and activate the release of 
proinflammatory mediators such as tumor necrosis factor (TNF), interleukin-1 (IL-
1) and interleukin-6 (IL-6), high-mobility group box-1 protein (HMGB-1), 
macrophage migratory inhibitory factor (MIF), platelet activating factor (PAF), nitric 
oxide (NO), and ecosonoids. Figure 2 below displays the interaction. 
 Figure 2: Activation and Interaction of Inflammatory Mediators in Sepsis (Jean-Baptiste,2007) 
 
LPS binds to the surface molecule CD14 on macrophages. CD14 lacks an 
endoplasmic domain; therefore, signaling is done through a transmembrane protein 
known as a “toll-like receptor” (TLR). There are currently 10 TLR’s that have been 
identified. Both the IL-1 receptor and TLR share the same endoplasmic domain and 
have similar apoptotic effects. TLR-4 recognizes gram-negative bacteria. Binding of 
the LPS/CD14 complex to TLR-4 activated nuclear factor kappa-beta through 
phosphorylation. Under normal conditions, NF-kb is in the cytoplasm and 
essentially inactive. The nuclear translocation of NF-kb promotes the production of 
cytokines via transcriptional regulation of target genes. The visual schematic of this 
can be seen in Figure 3 below.  
 
Figure 3: Cellular Responses to Infective Agents and TNF in the Immune and Target Cells (Jean-Baptiste). 
 
2.3.2 Platelet Function in Coagulation  
  
 As part of the coagulation cascade, platelet function plays large role, 
specifically in relation to non-specific inflammatory defense during times of severe 
infection.  A previous study was done to look at platelet function in septic multiple 
organ dysfunction syndrome (MODS).  The study evaluated adhesive functions of 
platelets in MODS in patients in the ICU. It was found that platelets are activated in 
septic patients and significant degranulation was found only in MODS patients 
(Yilamaz, 2005). 
 Platelet closure time (PCT) was first evaluated as a potential biomarker in a 
study performed with dogs. The study looked at the importance of PCT in dogs with 
endotoxemia (Bolton, 2007). The study found that short closure time has the 
potential to serve as an early diagnostic biomarker for endotoxemia and longer 
closure times could be used as a gauge of the severity of endotoxemia (Yilamaz, 
2005).  
2.4 Platelet Closure Time and Severe Sepsis at UMass Medical School  
 The hypothesis of this study is that platelet closure time will aid in 
identification of severe sepsis and septic shock in humans at an early stage and the 
degree of platelet closure time will identify the severity of the disease. A broad 
spectrum of patients will be enrolled and the severity of their illness will be 
determined by an APACHE II score (described in section 2.4.1 below). The platelet 
closure times will be analyzed along with their lactate levels to determine if there is 
any correlation.  
2.4.1 Platelet Closure Time 
 
 To establish platelet closure time in a blood sample, a platelet function assay 
(PFA) must be performed. The test measures both platelet adhesion and 
aggregation.  The PFA test is a rapid and accurate test of platelet function. The 
template bleeding time often gives poor and irreproducible results. The PFA test is 
performed with a laboratory analyzer that is known as the PFA-100. Small 
membranes that are coated with collagen and epinephrine or collagen and ADP are 
used. A blood sample is then passed through the membranes at rate to simulate the 
hemodynamics in the small capillaries. The platelets adhere to the membranes and 
form a small aperture in the center of each membrane. The time, in seconds, it takes 
to close the aperture is known as “closure time” (CT). The results of this test and 
what a normal closure time should be are still trying to be determined.  
2.4.2 Physiologic Scoring Systems  
 
 In order to compare the severity of illness of patients, this study uses the 
APACHE II system in order to score each patient’s severity of illness. The score 
directly correlates to a mortality rate prediction. Physiologic scores are assessed to 
compare illness severity immediately upon arrival to the Emergency Room, 
although this is not routinely done. It is crucial that these physiologic scores be 
obtained in the most proximal stage of the disease. Often by the time the patient is 
transferred to the ICU the scores may be higher or lower, due to the progression of 
the disease or the therapy administered. The initial physiologic scores that are 
evaluated in order to calculate the APACHE II score are: age, mean arterial pressure 
(MAP), serum potassium, serum sodium, hematocrit, WBC, serum creatinine, serum 
pH, bicarbonate levels, temperature, respiratory rate, and heart rate (Otero, 2006). 
3.0 Methodology 
 
3.1 Admission of Patients  
 
The target enrollment number of patients in this study is 50. The first 3 
patients were enrolled in 2009, these were the only patients enrolled before we 
started enrolling patients. The patients enrolled will range in the degree of illness.  
APACHE II scores are used to estimate mortality rate due to different signs 
established near the time of blood draw.  Over the course of this phase of the study 
from September 2010 through April 2011 (or whatever the real dates are), twelve 
patients were enrolled including the 3 in 2009. There were 15 blood samples drawn, 
due to the fact that three of the patients had two draws, peripheral and central.  
3.1.2 Patient criteria 
 
 In order for a patient to be eligible for the Platelet Closure Time Study they 
must have had at least two SIRS symptoms and presence of infection. The SIRS 
symptoms can be observed in Figure 3 below. 
 
Figure 4: SIRS Criteria 
These criteria allow for a broad spectrum of patients to be included. Some are 
enrolled with only SIRS symptoms while others already have severe sepsis or septic 
shock. The spectrum of different participants will give the study more merit and 
allow a more complete analysis of the relationships between sepsis and platelet 
closure time. Also incorporated in the study are exclusion criteria; patients must be 
18 year of age or older and pregnant patients and prisoners are not eligible.  
3.1.3 Obtaining patient consent 
 
After it was determined that a patient fit the criteria for the study, patient 
consent needed to be obtained prior to enrollment. There were two consent forms 
that needed to be signed by the participant and the primary investigator, Dr. Marie 
Mullen. The first form was to gain consent to analyze platelet closure time of 
previously drawn blood. The second form was to gain access to their medical 
records. Both of the consent forms needed to be signed before the patient was able 
to be enrolled in the study. Copies of the consent forms were given to the patient to 
keep.  
 The patient also had to be eligible to consent. If they were not coherent 
enough to consent themselves, a family member could consent on their behalf. This 
also applied to mentally ill patients.  
3.2 Blood Analysis 
 
 Once the patient consented, the researchers checked with the nurse to 
determine if there were orders to draw blood. If so, an extra blue top tube of blood 
was requested to be drawn.  The first blood sample received was usually from a 
peripheral draw within the first hour of the patient entering the Emergency Room. A 
second blue top tube was obtained if a central venous catheter was inserted. This 
typically occurred when a patient is diagnosed with severe sepsis or septic shock 
and early goal-directed therapy was needed.  
3.2.1 Analyze samples with PFA-100 within 24 hours of blood collection to obtain CT 
values for EPI cartridge and ADP cartridge 
 
The Platelet Function Analyzer (PFA-100) was used to analyze the blood 
collected in the blue top tube within 24 hours of the draw. First a blank is run, and 
then the ADP and EPI cartridges are loaded. Using a micropipette, 800 microliters of 
blood is loaded into each cartridge. The sample is then run through the machine in 
order to measure the platelet closure times.  
3.3 Results Interpretation 
 
 As patients were enrolled into the study they each had a data collection sheet 
with their assigned research number on it. The PFA-100 platelet closure time values 
were noted along with age, sex, anticoagulants taken, and the time of the blood 
draw. The results of the following tests ordered by the physician were also 
documented: lactate, ScVO2, platelet count, Partial Thromboplastin Time (PTT), 
Prothrombin Time (PT)/ International Normalized Ratio (INR), creatinine, and 
blood urea nitrogen count (BUN). All of this information was also entered into an 
excel spreadsheet.  
3.3.1 Information Obtained From Patient Records  
 
 From the patient’s medical records the time in the Emergency Department 
was recorded along with the length of stay in the Intensive Care Unit, the length of 
stay in the hospital, the number of days on a ventilator, and the amount of time on 
vasopressors. This information allows the researchers to follow the course of 
treatment for each patient and how their illness progressed.  
 Each patient was given an APACHE II score in order to compare the degree of 
illness for each patient in the study. In order to calculate the score using an 
electronic calculator the following information had to be obtained from the patient’s 
chart: 
 -Age    -Respiratory Rate 
 -Mean Arterial Pressure -Heart Rate 
 -Temperature  -Serum Sodium 
 -Serum Potassium  -Serum pH 
 -Bicarbonate   -Serum Creatine 
 -Blood Gas (if applicable)  -Glascow Score 
 
From the information entered an estimated mortality rate was calculated. This 
allows the study to compare the severity of illness for each patient. This additional 
information gathered was entered into a second Excel spreadsheet.  
3.3.2 Statistical Analysis 
 
There were a total of 12 cases and 15 blood draws. The patients were placed 
into two different groups based on their lactate levels. The first group had high 
lactate levels (4 or greater). The second group had normal or low lactate levels 
(lower than 4). The descriptives, such as: mean, standard deviation, minimum and 
maximum, variance, and range for each of the groups were calculated using SPSS. 
The Kolmogorov-Smirnov test of normality was performed to determine how to 
optimize the analysis by using parametric or non-parametric tests. Histograms show 
a graphical representation of both ADP and EPI values for both of the groups, high 
lactate and low lactate. Box-plots were also generated and show each groups 
variability. To analyze if the difference was due to chance or not, an independent T-
Test was run. The null hypothesis was that there was no real difference between the 
two groups’ platelet closure times. The assumptions of the test were that there was 
normality and similar variances in the two groups. As stated before, a Kolmogorov-
Smirnov Test was run to determine if the normality assumption could be made. 
Then the Levene’s Test was run to determine if the similar variances assumption 
could be made.  
3.3.2.1 Association of PCT and Lactate 
 
A linear regression analysis was used to determine if there was an 
association between platelet closure times and lactate levels. The dependent 
(outcome) variable was platelet closure time, which was continuous data. The 
independent (predictor) variable was lactate levels, which was also continuous data. 
The assumptions were that the relationship between two variables should be linear, 
the dependent variable, Y, distributed normally, and the variability of Y as assessed 
by variance or standard deviation should be the same for each value of X  proven. 
The linearity of the relationship was shown using a scatter plot. The normality of the 
dependent variable, platelet closure time, and the variance were determined using 
the Kolmogorov-Smirnov Test and the Levene’s test, as described above. The null 
hypothesis was that there was no relationship between the two variables. The linear 
regression was run to determine if the null hypothesis could be rejected. 
In order to determine if there were any confounding variables, gender, age, 
peripheral or central draw, platelet count, BUN and creatinine levels were noted for 
each patient in the two groups. These variables were compared with platelet closure 
time using linear regression analysis.  The null hypothesizes for each was that there 
was no relationship between platelet closure time and any of the additional 
variables. These results were all described in the results section. 
4.0 Results and Analysis 
 
Twelve patients were enrolled into the study with 15 blood draws. The 12 
patients were divided into two groups based upon their lactate levels. Patients in 
group 1 (seen throughout the SPSS figures below as group .00) the less sick patients, 
had lactate levels below 4 millimol/L. The second group is comprised of sicker 
patients, with lactate levels of 4 millimol/L or higher.  This is a very small sample 
size and therefore, difficult to interpret. The following tests are all not statistically 
significant most likely due to the fact of the sample size. The tests were run with this 
data set in order to show the statistical analysis that would be used when the study 
is complete.  
 The data collection Excel sheets with all the data collected for the study, are 
included in Appendix 1. It is difficult to determine whether or not there are any 
trends when looking at the data in this form. Before the data could be analyzed 
graphically the descriptives of the data needed to be determined, as seen in Table 2 
below. This includes values such as: mean, confidence intervals, median, variance, 
minimum, maximum, and range. This was done for both types of platelet closure 
times, ADP and EPI, as well as for both groups, high and low lactate levels.  
For the ADP platelet closure times there was not a large difference between 
the means of the two groups. Group 1 had an average of 142.3 seconds and Group 2 
had an average of 150.5 seconds. There was a greater difference in the medians 
between the two groups. With a small sample size the median can sometimes be a 
better representation than the mean. The EPI means were somewhat more varied 
but still not drastically different. The medians were also somewhat different but not 
drastic. This does not give a conclusive outlook on whether or not the sicker 
patients with higher lactate levels have longer platelet closure times. 
Table 2: Platelet Closure Time Group Descriptives: the group indicated as 0.00 is the low lactate group, 
while the group indicated as 1.00 is the high lactate group.  
 
Descriptives  
  Groups Statistic Std. Error 
ADP 0.00 Mean 142.2727 24.95162 
Median 132   
Variance 6848.418   
Std. 
Deviation 
82.75517 
  
Minimum 65   
Maximum 300   
Range 235   
Interquartile 
Range 
108 
  
Skewness 1.007 0.661 
1.00 Mean 150.5 39.20991 
Median 148.5   
Variance 6149.667   
Std. 
Deviation 
78.41981 
  
Minimum 65   
Maximum 240   
Range 175   
Interquartile 
Range 
151 
  
Skewness 0.101 1.014 
EPI 0.00 Mean 183.3636 25.60301 
Median 196   
Variance 7210.655   
Std. 
Deviation 
84.91557 
  
Minimum 68   
Maximum 300   
Range 232   
Interquartile 162   
Range 
Skewness -0.094 0.661 
1.00 Mean 227 15 
Median 226   
Variance 900   
Std. 
Deviation 
30 
  
Minimum 196   
Maximum 260   
Range 64   
Interquartile 
Range 
57 
  
Skewness 0.104 1.014 
 
 
4.1 Graphical Analysis 
Once the values were determined, histograms for both ADP and EPI PCT’s 
were generated in order to give a better graphical representation of the difference 
between the two groups. 
 
 
A) Group 1 (low lactate)          B) Group 2 (High Lactate) 
 
 
 
 
As can be seen in Figure 5, ADP platelet closure times across the patient samples 
ranged from a low of 65 seconds to a high of 300 seconds.  In the low lactate group, 
none of the eleven patients had levels below 200 seconds and the remaining two 
had values above 250 seconds.  However, in the high lactate group, 3 of the 4 had 
lactate levels below 200, representing about an equivalent fraction as in the low 
lactate group. The means for the two groups, 142 seconds and 150 seconds do not 
appear to be remarkably different and there is no discernable change in the pattern 
or distribution of values between the two groups.  
By contrast, in the EPI data for platelet closure time, 54% of the low lactate 
group had PCTs below 200, compared to only 25% of those in the high lactate group.  
While these data are not statistically significant due to the small sample size and the 
uneven group sizes, the trend is in keeping with our hypothesis that platelet closure 
time will be higher in patients with higher lactate levels, suggestive of increased 
severity of sepsis.   
In Figure 5A, the histogram for the first group’s ADP platelet closure times is 
somewhat skewed toward the left. This was also seen above in Table 2 with the 
skewness values. Even though it seems skewed, the differences may not be 
statistically significant. A test of normality will tell whether or not it is truly skewed. 
When a sample size is extremely small the histogram appearance can be deceiving.   
Figure 5B does not give us too much information as far as skewness and this is due 
to the fact that group 2 only has four values, all of which are different. With such a 
Figure 5: ADP Platelet Closure Time (seconds) for groups 0.00 (low lactate levels) (A) and 1.00 
(high lactate levels) (B). This shows the distribution of PCT’s within each group.  
small sample size in a group, skewness is not immediately evident from a histogram. 
Skewness tells how much the data trend sways from normality. Positive skewness 
indicates the data is skewed to the right and negative skewness indicates that the 
skewed to the left. Normality indicates the data has a bell curve trend.  This is 
important because normality is an assumption for many statistical tests. 
 
      
 
 
 
 
 
 
 
 
 
 
    A) Group 1 (Low Lactate)          B) Group 2 (High Lactate) 
 
Figure 6: EPI Platelet Closure Time Histograms for Groups 1(A) and 2(B). This shows the distribution of 
PCT’s within each group.  
Figure 6A and 6B show histograms for the EPI platelet closure times. Neither 
of the graphs shows an obvious skewness or trend in the data. It does show a 
hopeful trend in the fact that half of the low lactate patients has levels <200 seconds 
while none of the high lactate people did. This is not significant at the time but 
seeing a trend such as this early on can be potentially promising. This is due to the 
lack of data in the small sample size. It appears in this case that the EPI is not likely 
to be as sensitive as the ADP due to the fact that the trends below are more general 
than seen above. This could possibly be due to chance and thrown off by the small 
sample size. A definite conclusion would be able to be drawn about the difference 
between the ADP and EPI platelet closure times if the sample size where 
significantly larger than the current size of 15. ADP and EPI are different platelet 
mediators and therefore, could potentially have somewhat different affects on the 
platelets and PCT.  
 
 
 
 
A) ADP Platelet Closure Times          B) EPI Platelet Closure Times     
Figure 7 shows box and whisker plots for both ADP and EPI platelet closure 
times. Box and Whisker Plots are effective in order to show variability and outliers 
within the two groups.  Figure 7A shows that there is only a slight difference 
between the two groups. Group 1 has a significant outlier at 300 seconds where 
group 2’s values have less variability.  If the outlier were removes the mean for the 
low lactate group would be lower and the trend would be consistent with the 
hypothesis. This once again shows that the current trends, even with the small 
Figure 7: Box and Whisker Plots for both ADP and EPI Platelet Closure Times. This graphical 
representation is used in order to show variability. Figure A, shows ADP’s PCT’s for both group 0.00 
(low lactate) to the left and group 1.00 (high lactate) to the right. Figure B, shows EPI’s PCT’s for both 
groups as well. 
group size, are favoring in the right direction. It would have been ideal to see group 
1 with a lower median around 80 seconds and group two with a higher median 
around 250 seconds. The outcome we predicted is not seen here with our present 
data. The high lactate group (1.00) is, however, somewhat higher. With more 
patients enrolled in the study in the future it is possible that these two groups will 
differentiate from each other more as predicted in our initial hypothesis. Figure 7B 
below shows the low lactate group (0.00) does have a lower median than the second 
group, as established in Table 2. However, there is some of variability in group 0.00. 
With a greater sample size a better understanding would be able to be established. 
The graphic presentation gives a good outlook on potential trends. The statistical 
data does not tell us that without the outlier the data would look very similar to 
what was predicted with our hypothesis. According to the graphical representation 
as more patients are enrolled the statistical data will most likely improve as well. 
4.2 T-Test 
 
An independent t-test compares the mean scores of two groups on a given 
variable. It is used to determine if the difference between the means is due to chance 
or if there is a statistically significant difference. A statistically significant difference 
in this case would mean that there is a difference in platelet closure times between 
sicker patients with higher lactate levels and less sick patients with lower platelet 
closure times.  
  
4.2.1 T- Test Assumptions 
 
A Kolmogorov-Smirnov test of normality was used to see if the data is 
normally distributed or skewed. An idea of normality can be obtained from the 
histograms usually but due to the very small sample size it was nearly impossible to 
determine whether or not the data was truly normal by looking at the graphs. The 
null hypothesis is that the data distribution is normal. For both ADP and EPI both 
groups there was not enough information to reject the null hypothesis because the 
p-values shown in the Sig. column were greater than 0.05, therefore the null 
hypothesis was accepted. This means that the test is 95% confident that the data 
does follow a normal trend. In both cases group 1 did not produce a p-value. This is 
because the sample size is only 4 in this group and it is not large enough to make a 
true determination. This data indicated that the following statistical tests needed to 
be parametric tests. Non-parametric tests are typically used for small data sets; 
however, the assumptions for parametric tests were met, which indicated that 
parametric tests were needed.  
 
Tests of Normality 
 
Groups 
Kolmogorov-Smirnov
a
 Shapiro-Wilk 
 Statistic df Sig. Statistic df Sig. 
ADP .00 .225 11 .125 .846 11 .037 
1.00 .202 4 . .965 4 .809 
EPI .00 .189 11 .200
*
 .917 11 .294 
1.00 .237 4 . .925 4 .565 
a. Lilliefors Significance Correction 
*. This is a lower bound of the true significance. 
Figure 8: Kolmogorov-Smirnov Normality Test for both ADP and EPI platelet Closure Times. The Sig 
column indicates that for both groups the null hypothesis of normality is accepted. 
Figure 9 is a two-sample Kolmogorov-Smirnov Test. Instead of splitting ADP 
and EPI into groups 1 and 2 it tested if ADP or EPI as a whole had normal data. The 
null hypothesis was that the data follows a normal trend. In both cases there was 
not enough evidence to reject the null hypothesis because the p-values were greater 
than 0.05. This confirms the fact that parametric tests need to be used when testing 
this data set. The first assumption of a t-test is that the data follows a normal trend. 
This was verified by figures 8 and 9. 
The second assumption of a t-test is that the two groups being tested have 
approximately equal variance for the dependent variable, in this case platelet 
closure time. Figure 11 shows the Levene’s Test of equality of variances. The null 
hypothesis is that the variances are equal. For ADP the p-value is above 0.05 and the 
null hypothesis can be accepted. For EPI the p-value is less than 0.05 and the null 
hypothesis is rejected. The assumption is only valid for ADP platelet closure time 
values. The discrepancy between the two adhesion factors is probably not 
significant and only seen due to the small sample size at this time.  
Independent Samples Test 
 
Levene's Test for 
Equality of Variances 
t-test for Equality of 
Means 
F Sig. t df 
ADP Equal variances 
assumed 
.001 .970 -.172 13 
Equal variances 
not assumed 
  
-.177 5.644 
EPI Equal variances 
assumed 
6.118 .028 -.985 13 
Equal variances 
not assumed 
  
-1.471 12.955 
Figure 9: Levene's Test for Equality of Variances. The Sig Column indicates that equal variances are 
assumed for ADP, but not for EPI. EPI cannot assume equal variances as a result from this test. 
4.2.2 Independent T-Test Results 
 
The null hypothesis is that the two groups are not significantly different. For 
ADP equal variances can be assumed and the p-value seen in figure 10 is higher than 
0.05, so the null hypothesis is accepted. For EPI equal variances cannot be assumed, 
the p-value is still higher than 0.05 so the null hypothesis is accepted again. The 
conclusion from this test is that at this time there is no difference in platelet closure 
time between patients with high lactate levels and patients with low lactate levels. 
With a higher sample number and more platelet closure times a difference between 
the group means could possibly be established. 
 
 
 
Independent Samples Test 
 
t-test for Equality of Means 
Sig. (2-tailed) 
Mean 
Difference 
Std. Error 
Difference 
ADP Equal variances 
assumed 
.866 -8.22727 47.74637 
Equal variances not 
assumed 
.866 -8.22727 46.47580 
EPI Equal variances 
assumed 
.343 -43.63636 44.29120 
Equal variances not 
assumed 
.165 -43.63636 29.67346 
Figure 10: Parametric Independent T-Test. This test established that at this time there is no difference in 
PCT's between sicker patients with high lactate levels and less sick patients with low lactate levels. 
 
 
4.3 Linear Regression 
 
A linear regression was done to see if there is an association between lactate 
levels and platelet closure time. The hypothesis of the study is based on  this 
assumption. The predictor values were the groups because they were separated 
based on lactate levels. The higher lactate levels are in Group 2, the lower in Group 
1. Figure 11 shows the regression summary. The test is not statistically valid 
because the R squared value is very close to 0. If there is statistical significance the R 
squared value should be very close to 1. An assumption of the linear regression is 
that the data are nearly linear.  If it were linear the following ANOVA’s in Figure 12 
would be able to truly determine if there was an association. With more test 
subjects a linear relationship with an R squared value may be able to be established.  
 
A) ADP Linear Regression Summary 
Model Summary 
Model R R Square 
Adjusted R 
Square 
Std. Error of the 
Estimate 
1 .030
a
 .001 -.076 81.83206 
a. Predictors: (Constant), Lactate 
b. Dependent Variable: ADP 
 
 
B) EPI Linear Regression Summary 
Model Summary 
Model R R Square 
Adjusted R 
Square 
Std. Error of the 
Estimate 
1 .480
a
 .230 .171 69.00473 
a. Predictors: (Constant), Lactate 
b. Dependent Variable: EPI 
Figure 11: ADP (A) and EPI (B) Linear Regression Summaries. The conclusion from this test is that the 
data is not linear for either set of PCT's. 
Figure 12 is of an ANOVA. This test is not valid due to the fact that the R squared 
values were not close to 1 in Figure 11. The null hypothesis is that there is no 
association between platelet closure time (ADP) and lactate. The p-value is 
extremely high and therefore, the null hypothesis is accepted. Once again, this result 
is possibly due to the small sample size.  
A) ADP ANOVA 
ANOVA
b
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 77.410 1 77.410 .012 .916
a
 
Residual 87054.324 13 6696.486   
Total 87131.733 14    
a. Predictors: (Constant), Lactate 
b. Dependent Variable: ADP 
 
B) EPI ANOVA 
ANOVA
b
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 18490.519 1 18490.519 3.883 .070
a
 
Residual 61901.481 13 4761.652   
Total 80392.000 14    
a. Predictors: (Constant), Lactate 
b. Dependent Variable: EPI 
Figure 12: ADP (A) and EPI (B) ANOVA's. These ANOVA's prove that at this time there is no association 
between lactate levels and PCT's. 
4.4 PCT and Mortality Analysis 
 
 A linear regression was performed in order to determine if there is an 
association between both ADP and EPI Platelet Closure Times and mortality. In this 
case the mortality rate for each patient was calculated by determining his or her 
APACHE II score (This process is discussed in the Introduction). Neither of the R 
squared values is close to zero. This indicates that the data are not linear and the 
following ANOVA’s in Figure 14 are not statistically relevant. This is however, the 
statistical test that would be used in order to determine if there is an association 
when more patients have been enrolled.  
 
A) ADP Platelet Closure Times Vs. APACHE II Score (Mortality) 
 
Model Summary 
Model R R Square 
Adjusted R 
Square 
Std. Error of the 
Estimate 
1 .126
a
 .016 -.060 81.21976 
a. Predictors: (Constant), APACHEII 
 
 
B) EPI Platelet Closure Times Vs. APACHE II Score (Mortality) 
 
Model Summary 
Model R R Square 
Adjusted R 
Square 
Std. Error of the 
Estimate 
1 .208
a
 .043 -.030 76.91682 
a. Predictors: (Constant), APACHEII 
 
Figure 13: Linear Regression of Platelet Closure Time Vs. Mortality Rate (APACHE II Score). In both A and 
B the R squared value is close to zero indicating that the data is not linear. 
Figure 14 below is of an ANOVA. This test is used when the linear regression shows 
the data is linear. This is the actual test that shows if there is an association. The null 
hypothesis is that there is no association between the two variables (PCT and 
mortality). In both A and B the p-values located in the Sig. column are over 0.05. 
This means that there is not enough evidence to reject the null hypothesis and 
therefore, it is accepted. With more patients enrolled this result could possibly 
change.  
 
 
 
A) ADP ANOVA 
 
ANOVA
b
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 1375.296 1 1375.296 .208 .655
a
 
Residual 85756.437 13 6596.649   
Total 87131.733 14    
a. Predictors: (Constant), APACHEII 
b. Dependent Variable: ADP 
 
B) EPI ANOVA 
 
ANOVA
b
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 3481.427 1 3481.427 .588 .457
a
 
Residual 76910.573 13 5916.198   
Total 80392.000 14    
a. Predictors: (Constant), APACHEII 
b. Dependent Variable: EPI 
 
Figure 14: ANOVA between PCT and Mortality. The null hypothesis is accepted due to the high p-values in 
both A and B. 
4.5 Confounding Variables Analyses  
 
 Different variables that are present in a study can at times have an effect on 
the study. Some of these variables can be gender, age, peripheral or central blood 
draw, time of blood draw, whether a doctor or nurse draws the blood. In any study 
you need to determine which variables could possibly have an effect on the study. 
Some will be more prominent than others. In this case, ANOVA’s were performed 
between PCT and gender and PCT and age. This will tell if there is an association 
between the variables. If there is, then gender (or age) is a confounding factor and 
influencing the results of the study. If a variable is determined to be a confounding 
factor it needs to be addressed in the study protocol and how the study is going to 
compensate for it.  
4.5.1 Age 
 
 The Liner Regression in Figure 15 below indicates that the data is not linear. 
This does affect the ANOVA as stated above in Figure 13.  With a larger sample size 
this can become more linear in trend.  
 
A) ADP Linear Regression 
 
Model Summary 
Model R R Square 
Adjusted R 
Square 
Std. Error of the 
Estimate 
1 .103
a
 .011 -.066 81.43461 
a. Predictors: (Constant), Age 
 
B) EPI Linear Regression 
Model Summary 
Model R R Square 
Adjusted R 
Square 
Std. Error of the 
Estimate 
1 .265
a
 .070 -.001 75.83154 
a. Predictors: (Constant), Age 
Figure 15: Linear Regression for PCT verses Age. The R squared value indicated that the data is not 
linear. 
In Figure 16 below the ANOVA’s with both ADP and EPI platelet closure times 
indicates that there is no association between age and PCT. The null hypothesis is 
that there is not association. This is accepted because the p-values are higher than 
0.05. Age is not a confounding factor at this time.  
 
 
 
 
A) ADP ANOVA 
 
ANOVA
b
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 920.993 1 920.993 .139 .715
a
 
Residual 86210.740 13 6631.595   
Total 87131.733 14    
a. Predictors: (Constant), Age 
b. Dependent Variable: ADP 
 
B) EPI ANOVA 
 
ANOVA
b
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 5636.503 1 5636.503 .980 .340
a
 
Residual 74755.497 13 5750.423   
Total 80392.000 14    
a. Predictors: (Constant), Age 
b. Dependent Variable: EPI 
 
Figure 16: ANOVA between PCT and Age. Age is not a confounding factor because the null hypotheisis is 
accepted. 
4.5.2 Gender 
 
 The second possible confounding factor tested was gender. The linear 
regression for both ADP and EPI show that the data is not linear with the current 
sample size. This is show by the R squared values close to 0 in Figure 17.  
 
 
 
 
 
A) ADP Linear Regression  
  
Model Summary 
Model R R Square 
Adjusted R 
Square 
Std. Error of the 
Estimate 
1 .401
a
 .161 .096 74.99585 
a. Predictors: (Constant), Gender 
 
B) EPI Linear Regression 
 
Model Summary 
Model R R Square 
Adjusted R 
Square 
Std. Error of the 
Estimate 
1 .451
a
 .203 .142 70.19588 
a. Predictors: (Constant), Gender 
Figure 17: Linear Regression between PCT and Gender. The data is not linear. 
Gender is not a confounding factor at this time. The null hypothesis for the ANOVA’s 
in Figure 18 below is that there is no association between PCT and gender. This 
hypothesis is accepted because the p-values are greater than 0.05.  
 
A) ADP ANOVA 
 
ANOVA
b
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 14014.817 1 14014.817 2.492 .138
a
 
Residual 73116.917 13 5624.378   
Total 87131.733 14    
a. Predictors: (Constant), Gender 
b. Dependent Variable: ADP 
 
  
 
 
B) EPI ANOVA 
ANOVA
b
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 16335.000 1 16335.000 3.315 .092
a
 
Residual 64057.000 13 4927.462   
Total 80392.000 14    
a. Predictors: (Constant), Gender 
b. Dependent Variable: EPI 
Figure 18: ANOVA between PCT and Gender. There is no association therefore; gender is not a 
confounding factor at this time. 
5.0 Conclusion 
 
 The previously stated hypothesis was that platelet closure time will aid in 
early detection of sepsis. At this time, with the number of patients enrolled in the 
study it is not possible to determine if the hypothesis is true. Currently, the statistics 
show that platelet closure time does not aid in early detection of sepsis. There is 
presently no association between the known biomarker, lactate, and platelet closure 
time. The first goal to validate the correlation between platelet closure time (PCT) 
and sepsis was to analyze the PCT in 50 patients that fit the study criteria. After a 
period of six months only 12 patients were enrolled into the study. There is still 
hope that when 50 patients have been enrolled the correlation between PCT and 
sepsis will be able to be validated with statistical analysis.  
 The subsequent goal is to establish a correlation between lactate as 
biomarker and PCT. As the results at this time indicate, the correlation between 
lactate and PCT is nonexistent. With more time and patients there will possibly be a 
change in the outcome of the related statistical analyses.  
Even though the results to date are inconclusive this study can still produce 
results that will influence how sepsis is diagnosed. Due to the complexity of sepsis, 
early detection at this point is a challenge. If a larger sample size establishes that 
PCT does aid in early detection of sepsis by validating an association between PCT 
and lactate levels, the result of an early detection biomarker could lower sepsis 
mortality rates and potentially allow for more effective and cost-friendly 
treatments. On the other hand, if the larger sample size proves that there is no 
association between PCT and early detection of sepsis, the researchers can predict 
that the early detection biomarker is located further down the inflammatory 
cascade after the point where the coagulation cascade intersects.  
At this time the statistical analyses are not significant due to the small sample 
size. However, the graphical representations are very promising. They show that the 
current trend is what the hypothesis predicted. If the trends continue in this manner 
as more patients are enrolled the outcome of this study is quite promising. It is 
difficult to enroll a lot of patients due to the exclusion criteria and other 
confounding factors that may affect the data, such as underlying disease or 
autoimmune disorders. Once the confounding factors are established outliers, such 
as the one seen in the box and whisker plots may be eliminated in order to gain a 
more accurate representation of the data. The study is still at an early stage but 
there are some hopeful indications for the future of the study.  
 
 
6.0 Appendix 
 
Table 3: Data Collection Sheet 1 
 
ADP EPI Groups APACHE II Age Gender 
184 196 0 11 73 0 
300 230 0 9 53 0 
76 101 0 2 53 1 
65 78 0 2 49 1 
69 104 0 16 83 0 
81 68 0 16 59 0 
132 284 0 10 72 0 
275 300 0 16 83 0 
151 166 0 13 42 0 
156 263 0 17 53 0 
76 227 0 7 74 0 
65 196 1 11 73 0 
240 244 1 3 44 0 
109 208 1 10 69 1 
188 260 1 13 72 0 
Table 4:  Data Collection Sheet 2 
 
Research 
Number Time of Draw 
Peripheral  
or Central ADP(sec) EPI(sec) Lactate ScVO2 Platelets PTT PT/INR BUN/Cret 
1001 1430 central 184 - 0.75/4.0   - - 0/1.5 
1002 1236 peripheral >300 227 3.7 - 104 29.5 19.2/1.9 14/.66 
1003 0200/0700 central 81/86 68/65 2.49 68% 243 - 38.8/3.4 43/8.5 
1004 1320 peripheral >300 
terminated due 
to flow 
obstruction 0.9 - 97 37.4 10/.9 29/.77 
1005 1100 peripheral 156 263 3.4 - 116 27.3 10.1/1.0 25/4.97 
1006 1545/1818 peripheral/central 188/132 NA/284 5.7/2.57 NA/63% 142/120 28.7 13/1.2 17/1.19 
1007 1425 peripheral 109/113 >208/>174 4.3 _ 189 38.5 62/6.0 24/99 
1008 1405 peripheral >240(insufficient) 244 - - 67 - - 14/1.08 
1009 1300/1600 central/central >275/69 >300/104 3.0/1.51 67%/67% 319/297 38.7/NA 14/1.4/NA 92/3.61 
1010 1351 peripheral >151 >166 - - 27 31.5 14.8/1.4 13/1.66 
1011 1705 peripheral 76 101 1.1 _ 268 25.3 10.7/1.0 14/0.95 
1012 1619 peripheral 65 78 1.5 _ 344 33.1 11/1.0 8/1.14 
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